LX4211 is an orally-delivered dual SGLT1/2 inhibitor approved for T1DM and exhibits a 20-fold higher potency for SGLT2 over SGLT1 [76]; the involvement of SGLT2 inhibition in this synergism cannot be ruled out. The gene discussed is SLC5A1; the disease is type 1 diabetes mellitus.